Stunning. Nothing but last-century Alzheimer's perspectives.
Just read the webpage. Same old same old. Lots of failed tries to eliminate beta-amyloid plaques and tau tangles. Nothing close to success. Then, present Standard of Care (SOC) acetlycholinesterase inhibitors, yielding but a few weeks or months of symptomatic progression relief.
Is anyone wondering why AVXL has not markedly appreciated? Perspectives and understandings such as the author presents on this webpage pervade pharmaceutical commentaries.
Clearly, the mechanistic details, efficacy, safety, and applications of Anavex 2-73 are virtually unknown by the investment advisory community. What little (inadequately) is known is summarily dismissed as just another ensuing Alzheimer's treatment fiasco. There have been so many of those commentators fail even to take the time to learn the unique chemistry of the Anavex molecules. Poor reporting it is.
As I've contended previously, nothing much is going to change until Phase 3 data are released, showing in great magnitude all (and perhaps more) than the Phase1/Phase2 trial in Australia revealed.
The vast majority of investors invest on the basis of anticipated share price increases and dividend returns. The underlying, enabling hard science is unknown and/or irrelevant. We can lay out the science in the greatest detail here all we want. It will make no difference. Hard neuron science simply is, and will not, play any part in the AVXL share price. The reporting of drastically-decreased (or even just stabilized) symptoms in dozens upon dozens of the upcoming Phase 3 clinical trial will do the trick. Money can be reliably envisioned from such data.
